TEMOZOLOMIDE 🗂ïļ āļ§āļīāļ˜āļĩāļĢāļąāļšāđ‚āļšāļ™āļąāļŠ

āđāļšāļĢāļ™āļ”āđŒ: TEMOZOLOMIDE

TEMOZOLOMIDE   TEMOZOLOMIDE temozolomide is an alkylating agent used to treat serious brain cancers; most commonly as second line treatments for astrocytoma and as the first line treatment

TEMOZOLOMIDE on september 14, 2023, the food and drug administration (fda) approved updated labeling for temozolomide (temodar, merck) under project āļžāļĢāđ‰āļ­āļĄāđ€āļžāļĒāđŒ temozolomide āļŠāļĨāđ‡āļ­āļ•āļ‚āļąāđ‰āļ™āļ•āđˆāļģ 1 āļšāļēāļ— common side effects of temozolomide are nausea, fatigue, constipation, and more there are also less common and very rare side effects, which we discuss here temozolomide āļ§āļīāļ˜āļĩāļĢāļąāļšāđ‚āļšāļ™āļąāļŠ

TEMOZOLOMIDE temozolomide is an alkylating agent used to treat glioblastoma multiforme and refractory anaplastic astrocytoma temozolomide āđ€āļ§āđ‡āļšāļ„āļēāļŠāļīāđ‚āļ™āļ—āļĩāđˆāļ”āļĩāļ—āļĩāđˆāļŠāļļāļ” temozolomide is an alkylating agent used to treat glioblastoma multiforme and refractory anaplastic astrocytoma temozolomide āđ‚āļšāļ™āļąāļŠ100%

āļŋ1,670
āļŋ3,711 -55%
āļˆāļģāļ™āļ§āļ™
āļˆāļģāļŦāļ™āđˆāļēāļĒāđ‚āļ”āļĒ


Date Modified: 2024-10-13 16:28:03